8-K: Carisma Therapeutics Faces Nasdaq Delisting, Shifts to OTC

Carisma Therapeutics Inc. received a delisting notice from Nasdaq, with trading to cease on October 13, 2025, and plans to move to the OTCID market tier while pursuing an orderly wind-down.

Summary

• Carisma Therapeutics Inc. received a delisting determination letter from The Nasdaq Stock Market LLC on October 9, 2025.
• The company's common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
• Carisma Therapeutics does not plan to appeal Nasdaq's determination.
• The company has received approval to list its common stock on the OTCID market tier, with trading expected to commence on October 13, 2025, under the symbol CARM.
• Carisma Therapeutics expects to pursue an orderly wind down of its remaining operations and monetize assets.
• It is unlikely that a meaningful amount of cash will be available for distribution to stockholders during the wind-down or dissolution.

Sentiment

Score: 1

Explanation: The filing indicates severe financial distress, including delisting from Nasdaq, a planned wind-down of operations, and an explicit statement that it is unlikely stockholders will receive a meaningful distribution. This represents a near-total loss for equity holders.

Positives

• Approval received to list common stock on the OTCID market tier, allowing for continued, albeit limited, trading.

Negatives

• Received a delisting determination letter from Nasdaq.
• Common stock will be suspended from trading on Nasdaq effective October 13, 2025.
• The company does not plan to appeal the delisting decision.
• Unlikely that there will be a meaningful amount of cash available for distribution to stockholders in connection with a wind down or dissolution.
• No guarantee that a broker will continue to make a market in the common stock on the OTCID market tier.

Risks

• Risks associated with the company's ability to commence trading on the OTCID market tier.
• Risks related to the company's ability to identify and complete asset monetization transactions.
• Risks concerning the company's ability to preserve its existing cash resources.
• Risks regarding the company's ability to continue as a going concern.
• Risks associated with the company's ability to execute a planned orderly wind down.
• General business risks as detailed in previous SEC filings (Form 10-K for December 31, 2024, and Form 10-Q for June 30, 2025).

Future Outlook

Carisma Therapeutics expects its common stock to commence trading on the OTCID market tier on October 13, 2025. The company plans to continue efforts to sell or monetize its remaining assets and pursue an orderly wind down of operations. There is an expectation that a meaningful amount of cash will not be available for distribution to stockholders. The company may also file a Form 15 with the SEC to suspend its reporting obligations after the Nasdaq delisting.

Management Comments

• The Company does not plan to appeal Nasdaq's determination.
• The Company expects its common stock will commence trading on the OTCID market tier at the open of business on October 13, 2025.
• The Company expects to continue to attempt to sell or otherwise dispose of or monetize its remaining assets and pursue an orderly wind down of its remaining operations.
• It is unlikely that there will be a meaningful amount of cash available for distribution to stockholders in connection with a wind down of the Company's operations or a dissolution and liquidation of the Company.

Industry Context

This event highlights the significant challenges faced by small-cap biotechnology companies, particularly those unable to meet listing requirements or achieve commercial viability. Delisting from a major exchange like Nasdaq often signals severe operational or financial distress, leading to reduced liquidity and investor confidence, a common risk in the highly competitive and capital-intensive biotech sector.

Stakeholder Impact

• Shareholders: Significant negative impact due to delisting, reduced liquidity, potential loss of investment, and unlikely meaningful cash distribution during wind-down.
• Employees: Implied negative impact due to the wind-down of operations, likely leading to job losses.
• Creditors: Potential impact on recovery of debts depending on asset monetization outcomes.

Next Steps

• Common stock to commence trading on the OTCID market tier on October 13, 2025.
• Continue efforts to sell or dispose of or monetize remaining assets.
• Pursue an orderly wind down of remaining operations.
• Potentially file a Form 15 with the SEC to suspend reporting obligations after Nasdaq delisting.

Key Dates

Recommendation

The company is being delisted from Nasdaq, does not plan to appeal, and is pursuing an orderly wind-down of operations. Management explicitly states it is unlikely there will be a meaningful amount of cash available for distribution to stockholders. While trading may continue on the OTCID market, liquidity will be severely impaired, and the long-term outlook for equity holders is extremely poor, indicating a near-total loss of investment.

Keywords

Carisma Therapeutics, CARM, Nasdaq delisting, OTC Markets, OTCID, wind down, asset monetization, biotechnology, pharmaceuticals, SEC filing, 8-K